Multiple Myeloma Clinical Trial
Official title:
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Verified date | October 2022 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
Status | Completed |
Enrollment | 117 |
Est. completion date | October 21, 2021 |
Est. primary completion date | January 17, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - = 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination - Documented refractory or relapsed and refractory multiple myeloma - Refractory to proteosome inhibitor and lenalidomide, and to last treatment - Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment - Measurable disease at screening - Eastern Cooperative Oncology Group (ECOG) performance status = 2 Exclusion Criteria: - Active plasma cell leukemia - Prior treatment with pomalidomide - Unable to tolerate thromboembolic prophylaxis while on the study - Prior autologous stem cell transplant within 12 weeks - Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C |
Country | Name | City | State |
---|---|---|---|
Australia | Local Institution | South Brisbane | Queensland |
Canada | CISSS de l'Outaouais | Gatineau | Quebec |
Canada | Local Institution | London | Ontario |
Canada | Local Institution - 0048 | Montreal | Quebec |
France | Local Institution - 0022 | Nantes Cedex 1 | |
France | Local Institution - 0021 | Paris Cedex 12 | |
France | Local Institution - 0020 | Pessac | |
France | Local Institution - 0019 | Poitiers Cedex | |
France | Local Institution | Saint Pierre Cedex | |
Germany | Universitaetsklinikum Carl Gustav Carus | Dresden | |
Germany | Universitaetsklinikum Freiburg | Freiburg | |
Germany | St. Barbara-Klinik | Hamm | |
Germany | Local Institution - 0041 | Heidelberg | |
Germany | Local Institution - 0056 | Kiel | |
Germany | Klinikum Der Johannes Gutenberg Universitaet Mainz | Mainz | |
Germany | Universitaetsklinikum Tuebingen | Tuebingen | |
Greece | Alexandra General Hospital Of Athens | Athens | |
Greece | Laiko University Hospital | Athens | |
Italy | Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona | Ancona | |
Italy | A. O. U. Di Bologna, Policlinico S. Orsola Malpighi | Bologna | |
Italy | Azienda Ospedaliera Universitaria Careggi | Firenze | |
Italy | Local Institution | Roma | |
Italy | Universita' La Sapienza | Roma | |
Italy | Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino | Torino | |
Japan | Local Institution - 0067 | Kasama-shi | |
Japan | Local Institution - 0031 | Kyoto-shi | Kyoto |
Japan | Local Institution - 0069 | Morioka-shi | Iwate |
Japan | Local Institution - 0030 | Nagoya-shi | Aichi |
Japan | Local Institution - 0029 | Niigata-shi | Niigata |
Japan | Local Institution - 0032 | Okayama | |
Japan | Local Institution - 0027 | Shibuya-ku | Tokyo |
Japan | Local Institution - 0028 | Tachikawa-shi | Tokyo |
Netherlands | Local Institution | Amsterdam | |
Netherlands | Local Institution | Groningen | |
Netherlands | Local Institution | Maastrict | |
Netherlands | Local Institution | Utrecht | |
Poland | Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych | Chorzow | |
Poland | Local Institution | Lublin | |
Poland | Oddzial Hematologii i Transplantacji Szpiku | Poznan | |
Spain | Local Institution | Barcelona | |
Spain | Local Institution - 0024 | Madrid | |
Spain | Local Institution | Pamplona | Navarra |
Spain | Local Institution | Valencia | |
United States | Winship Cancer Institute | Atlanta | Georgia |
United States | Beth Israel Comprehensive Cancer Center | Boston | Massachusetts |
United States | Dana Farber Cancer Institute. | Boston | Massachusetts |
United States | Carolinas Healthcare System | Charlotte | North Carolina |
United States | Rush University Medical Center | Chicago | Illinois |
United States | St Francis Hospital | Greenville | South Carolina |
United States | Investigative Clinical Research Of Indiana, Llc | Indianapolis | Indiana |
United States | Tennessee Cancer Specialists | Knoxville | Tennessee |
United States | Northern Utah Associates | Ogden | Utah |
United States | Va Pittsburgh Healthcare System | Pittsburgh | Pennsylvania |
United States | Rochester General Hospital | Rochester | New York |
United States | University Of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb | AbbVie, Celgene |
United States, Australia, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) | PFS is defined as the time from randomization to the date of the first documented tumor progression or death due to any cause. Progressive disease response criteria were defined as an increase of 25% from lowest response value in any one or more of the following:
1. Serum M-component and/or 2. Urine M-component and/or 3. Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels 4. Bone marrow plasma cell percentage; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder |
From randomization to date of progression or death (up to approximately 21 months) | |
Secondary | Objective Response Rate (ORR) | ORR is defined as the percentage of participants who achieved a best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) using the modified International Myeloma Working Group (IMWG) criteria described as follows, as per investigator's assessment
CR: Negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in bone marrow sCR: CR, as defined above, plus the following: Normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >= 90% reduction in serum M-protein level plus urine M-protein level < 100 mg per 24 hour PR: >= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >= 90% or to < 200 mg per 24 hour. |
From first dose to disease progression (up to approximately 21 months) | |
Secondary | Overall Survival (OS) | OS is the time from randomization to the date of death from any cause. The survival time for participants who had not died was censored at the last known alive date. OS was censored at the date of randomization for subjects who were randomized but had no follow-up. | From randomization to death (up to approximately 52 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |